PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
153.33%
Growth of 153.33% while CRVO shows flat revenue. Bruce Berkowitz would examine growth quality advantage.
-27.15%
Cost reduction while CRVO shows 15.17% growth. Joel Greenblatt would examine competitive advantage.
73.30%
Positive growth while CRVO shows decline. John Neff would investigate competitive advantages.
89.46%
Margin change of 89.46% while CRVO shows flat margins. Bruce Berkowitz would examine quality advantage.
8.30%
R&D growth less than half of CRVO's 138.58%. David Dodd would verify if efficiency advantage is sustainable.
28.80%
G&A growth while CRVO reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.70%
Operating expenses growth less than half of CRVO's 45.36%. David Dodd would verify sustainability.
14.70%
Total costs growth less than half of CRVO's 45.36%. David Dodd would verify sustainability.
-100.00%
Interest expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
-27.15%
D&A reduction while CRVO shows 3.85% growth. Joel Greenblatt would examine efficiency.
-16.20%
EBITDA decline while CRVO shows 0.00% growth. Joel Greenblatt would examine position.
54.13%
Margin change of 54.13% while CRVO is flat. Bruce Berkowitz would examine quality.
-15.23%
Both companies show declining income. Martin Whitman would check industry conditions.
54.52%
Margin change of 54.52% while CRVO is flat. Bruce Berkowitz would examine quality.
98.15%
Other expenses growth above 1.5x CRVO's 38.61%. Michael Burry would check for concerning trends.
-12.38%
Both companies show declining income. Martin Whitman would check industry conditions.
55.64%
Margin change of 55.64% while CRVO is flat. Bruce Berkowitz would examine quality.
-98.15%
Both companies reducing tax expense. Martin Whitman would check patterns.
-9.33%
Both companies show declining income. Martin Whitman would check industry conditions.
56.84%
Margin change of 56.84% while CRVO is flat. Bruce Berkowitz would examine quality.
-5.41%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-8.33%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
2.98%
Share count reduction below 50% of CRVO's 0.01%. Michael Burry would check for concerns.
2.03%
Diluted share reduction below 50% of CRVO's 0.01%. Michael Burry would check for concerns.